InMed Pharmaceuticals (INM) EBIT (QoQ) (2021 - 2026)
InMed Pharmaceuticals (INM) EBIT (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | InMed Pharmaceuticals | 6.44 Mn | 1.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.19% |
| Dec 31, 2025 | -15.49% |
| Sep 30, 2025 | 26.23% |
| Jun 30, 2025 | -29.35% |
| Mar 31, 2025 | 15.35% |
| Dec 31, 2024 | -29.92% |
| Sep 30, 2024 | 14.71% |
| Jun 30, 2024 | -10.30% |
| Mar 31, 2024 | -12.12% |
| Dec 31, 2023 | 38.46% |
| Sep 30, 2023 | -450.94% |
| Jun 30, 2023 | 77.46% |
| Mar 31, 2023 | 2.80% |
| Dec 31, 2022 | 38.09% |
| Sep 30, 2022 | 45.15% |
| Jun 30, 2022 | -84.20% |
| Mar 31, 2022 | 17.91% |
| Dec 31, 2021 | -45.11% |